CAS Number85650-52-8
SynonymsZispin; (14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2.1-A]PYRIDO[2.3-C][2]BENZAZEPINE; Mirtazapin; 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE; Remeron; ORG-3770; UNII:A051Q2099Q; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; MIRTAZEPINE; 2-Methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine; Mirtazanine; Avanza; MFCD00865427; MIRTAZAPINE ANHYDRUOS; EINECS 288-060-6
Molecular FormulaC17H19N3
Molecular Weight265.35
Purity98%
Density1.2±0.1 g/cm3
Boiling Point432.4±45.0 °C at 760 mmHg
Melting Point114-116ºC
Appearancewhite solid
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 85650-52-8 |
| Catalog No. | 2A-9011463 |
| Chinese Name | 米氮平 |
| Synonyms | Zispin; (14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2.1-A]PYRIDO[2.3-C][2]BENZAZEPINE; Mirtazapin; 1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE; Remeron; ORG-3770; UNII:A051Q2099Q; 2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; MIRTAZEPINE; 2-Methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine; Mirtazanine; Avanza; MFCD00865427; MIRTAZAPINE ANHYDRUOS; EINECS 288-060-6 |
| Molecular Formula | C17H19N3 |
| Molecular Weight | 265.35 |
| Purity | 98 |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 432.4±45.0 °C at 760 mmHg |
| Melting Point | 114-116ºC |
| Appearance | white solid |
| Water Solubility | DMSO: ~8 mg/mL, soluble |
| Storage Condition | Store at RT |
| Application | Mirtazapine is an antidepressant 5-HT receptor inhibitor. |
| HTC | 2933990090 |
| MDL Number | MFCD00865427 |
| SMILES | CN1CCN2C(C1)c3ccccc3Cc4cccnc24 |
| InChI | 1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 |
| InChI Key | RONZAEMNMFQXRA-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | Transport |
| MSDS | msds/11463_1_85650_52_8.pdf |
| Bioactivity | Mirtazapine is a potent tetracyclic antidepressant.Target: 5-HT ReceptorMirtazapine, the novel antidepressant, has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors [1].Mirtazapine appears to have a substantial ameliorating effect on hot flushes and perspiration bouts. It is postulated that the 5-HT(2A) blocking properties of mirtazapine is accounted in the symptomatic relief of hot flushes [2]. After 4-24 weeks of treatment, mirtazapine induced downregulation of platelet alpha(2A)-adrenoceptors (up to 34%) and Galphai proteins (up to 28%), and the upregulation of GRK 2 (up to 30%). Treatment with mirtazapine reversed this abnormality and induced downregulation of alpha(2A)-adrenoceptor/Galphai complex [3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Neurological Disease References [1]. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64. [2]. Waldinger, M.D., H.H. Berendsen, and D.H. Schweitzer, Treatment of hot flushes with mirtazapine: four case reports. Maturitas, 2000. 36(3): p. 165-8. [3]. Garcia-Sevilla, J.A., et al., Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology, 2004. 29(3): p. 580-8. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 432.4±45.0 °C at 760 mmHg Melting Point 114-116ºC Molecular Formula C17H19N3 Molecular Weight 265.353 Flash Point 215.3±28.7 °C Exact Mass 265.157898 PSA 19.37000 LogP 2.75 Vapour Pressure 0.0±1.0 mmHg at 25°C Index of Refraction 1.668 InChIKey RONZAEMNMFQXRA-UHFFFAOYSA-N SMILES CN1CCN2c3ncccc3Cc3ccccc3C2C1 Storage condition Store at RT Water Solubility DMSO: ~8 mg/mL, soluble |
| Use of | Mirtazapine is a potent tetracyclic antidepressant.Target: 5-HT ReceptorMirtazapine, the novel antidepressant, has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors [1].Mirtazapine appears to have a substantial ameliorating effect on hot flushes and perspiration bouts. It is postulated that the 5-HT(2A) blocking properties of mirtazapine is accounted in the symptomatic relief of hot flushes [2]. After 4-24 weeks of treatment, mirtazapine induced downregulation of platelet alpha(2A)-adrenoceptors (up to 34%) and Galphai proteins (up to 28%), and the upregulation of GRK 2 (up to 30%). Treatment with mirtazapine reversed this abnormality and induced downregulation of alpha(2A)-adrenoceptor/Galphai complex [3]. Properties Articles23 Name Mirtazapine Synonym More Synonyms Mirtazapine Biological Activity Description Mirtazapine is a potent tetracyclic antidepressant.Target: 5-HT ReceptorMirtazapine, the novel antidepressant, has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors [1].Mirtazapine appears to have a substantial ameliorating effect on hot flushes and perspiration bouts. It is postulated that the 5-HT(2A) blocking properties of mirtazapine is accounted in the symptomatic relief of hot flushes [2]. After 4-24 weeks of treatment, mirtazapine induced downregulation of platelet alpha(2A)-adrenoceptors (up to 34%) and Galphai proteins (up to 28%), and the upregulation of GRK 2 (up to 30%). Treatment with mirtazapine reversed this abnormality and induced downregulation of alpha(2A)-adrenoceptor/Galphai complex [3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Research Areas >> Neurological Disease References [1]. Anttila, S.A. and E.V. Leinonen, A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev, 2001. 7(3): p. 249-64. [2]. Waldinger, M.D., H.H. Berendsen, and D.H. Schweitzer, Treatment of hot flushes with mirtazapine: four case reports. Maturitas, 2000. 36(3): p. 165-8. [3]. Garcia-Sevilla, J.A., et al., Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology, 2004. 29(3): p. 580-8. Chemical & Physical Properties Molecular Formula C17H19N3 Exact Mass 265.157898 PSA 19.37000 Index of Refraction 1.668 InChIKey RONZAEMNMFQXRA-UHFFFAOYSA-N Storage condition Store at RT |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: No dangerous goods IMDG Code: No dangerous goods International Air Transport Dangerous Regulations: No dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special precautions for users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Mevastatin | 73573-88-3 | 2A-9011426 |
| Miconazole nitrate | 22832-87-7 | 2A-9011436 |
| Midazolam | 59467-64-0 | 2A-9011438 |
| Miglitol | 72432-03-2 | 2A-9011445 |
| Minocycline hydrochloride | 13614-98-7 | 2A-9011457 |
| Moexipril | 103775-10-6 | 2A-9011482 |
| Mometasone furoate | 83919-23-7 | 2A-9011486 |
| Montelukast sodium | 151767-02-1 | 2A-9011498 |
| Morphine N-oxide | 639-46-3 | 2A-9011507 |
| Moxifloxacin hydrochloride | 186826-86-8 | 2A-9011514 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS